Recurrent and Metastatic Head and Neck Cancers
Publication Date: December 14, 2022
Key Points
Key Points
- Head and neck cancers frequently arise from the oral cavity, oropharynx, larynx, hypopharynx, or nasopharynx, and more rarely from salivary glands or paranasal sinuses.
- Immune-checkpoint inhibitors (ICIs) are now approved as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), with or without chemotherapy.
- The guideline provides recommendations regarding immunotherapy and biomarker testing for this diverse and complex group of diseases.
Treatment
...atment
...dation 1.1Programmed death-ligand 1 (PD-L1) i...
...endation 1.2PD-L1 combined positive scor...
...ion 1.3Tumor mutational burden (TMB)...
...1.4TMB ≥10 should be interpreted as high and c...
...commendation 2.1Pembrolizumab monotherapy...
...dation 2.2Pembrolizumab, platinum, and 5-FU may b...
...tion 3.1Pembrolizumab or nivolumab should be...
...dation 4.1Toripalimab, camrelizumab o...
...ecommendation 4.2Programmed cell death...
...5.1For patients with oligometastat...
....1Pembrolizumab may be offered to patients with...
...endation 6.2Pembrolizumab may be offered...
...iomarkers and Recommendations by PD-L1 Status...
...2. Recommendations by Subtype...